Insulet Shares Are Trading Higher Amid Strength in Diabetes-related Stocks Following Weight Loss Data From Novo Nordisk.

Benzinga12/21 03:02

DexCom, Insulet, Tandem Benefit From Novo Nordisk CagriSema Data

Seeking Alpha12/21 01:10

Executive VP Of Insulet Sold 26% Of Their Shares

Simply Wall St12/20 18:05

Insulet Corporation (NASDAQ:PODD) Delivered A Better ROE Than Its Industry

Yahoo Finance12/20 00:57

Insulet Is Maintained at Overweight by JP Morgan

Dow Jones12/13 03:47

Nephron Research Adjusts Price Target on Insulet to $310 From $285

MT Newswires12/13 00:31